Long-term study of saroglitazar for PBC with cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with primary biliary cholangitis (PBC).
- You are either on a stable dose of ursodeoxycholic acid (UDCA) for at least 6 months, or you cannot take UDCA and haven't taken it in the last 3 months.
- You have evidence of cirrhosis with specific blood test results (elevated ALP and bilirubin not too high).
- You do not have other liver diseases like hepatitis B or C, or severe liver complications (like being on a transplant list).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called seladelpar for people with primary biliary cholangitis (PBC) and cirrhosis, a form of liver scarring. The goal is to see if it can help improve liver health and reduce symptoms.
This trial tests a new oral medication, saroglitazar magnesium, for people with Primary Biliary Cholangitis (PBC) who have not improved enough on standard therapy (UDCA) or cannot tolerate it. The goal is to see if it can help control liver enzymes and improve outcomes.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This trial tests a combination of two experimental drugs (seladelpar and cilofexor) for people with primary biliary cholangitis (PBC) who have not responded well to standard treatment. The goal is to see if these drugs can improve liver health and reduce symptoms.
This study looks at how well two medicines, ursodiol and seladelpar, work together for people with primary biliary cholangitis (PBC), a liver disease. It may help doctors understand the best way to treat PBC and improve liver health.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.